Intranasal sufentanil for cancer-associated breakthrough pain

Area of Science:

• Palliative Care
• Pain Management
• Pharmacology

Background:

• Cancer-associated breakthrough pain presents a significant challenge in palliative care.
• Existing opioid therapies may not always provide rapid or sufficient relief for breakthrough pain episodes.

Purpose of the Study:

• To evaluate the efficacy, safety, and patient acceptability of intranasal sufentanil for cancer-associated breakthrough pain.
• To assess the effectiveness of intranasal sufentanil delivered via a patient-controlled analgesia device.

Main Methods:

• A prospective, open-label, observational study conducted in three Australian inpatient palliative care units.
• 30 opioid-tolerant patients with cancer breakthrough pain received intranasal sufentanil via a patient-controlled device.
• Outcomes measured included pain scores, need to revert to prior medication, patient preference, and adverse effects.

Main Results:

• Significant reductions in pain scores were observed at 15 and 30 minutes post-administration (P < 0.0001).
• Only 6% of episodes required reversion to previous breakthrough medication.
• 77% of patients rated intranasal sufentanil as superior to their previous medication, with a low incidence of mild adverse effects.

Conclusions:

• Intranasal sufentanil offers rapid-onset, effective analgesia for cancer breakthrough pain in palliative care.
• It is a practical, safe, and well-accepted option for managing breakthrough pain episodes.
• The patient-controlled device enhances usability and patient satisfaction in this setting.